Abstract

Sickle cell disease (SCD) is the monogenic hemoglobinopathy where mutated sickle hemoglobin molecules polymerize to form long fibers under deoxygenated state and deform red blood cells (RBCs) into predominantly sickle form. Sickled RBCs stick to the vascular bed and obstruct blood flow in extreme conditions, leading to acute painful vaso-occlusion crises (VOCs) - the leading cause of mortality in SCD. Being a blood disorder of deformed RBCs, SCD manifests a wide-range of organ-specific clinical complications of life (in addition to chronic pain) such as stroke, acute chest syndrome (ACS) and pulmonary hypertension in the lung, nephropathy, auto-splenectomy, and splenomegaly, hand-foot syndrome, leg ulcer, stress erythropoiesis, osteonecrosis and osteoporosis. The physiological inception for VOC was initially thought to be only a fluid flow problem in microvascular space originated from increased viscosity due to aggregates of sickled RBCs; however, over the last three decades, multiple molecular and cellular mechanisms have been identified that aid the VOC . Activation of adhesion molecules in vascular endothelium and on RBC membranes, activated neutrophils and platelets, increased viscosity of the blood, and fluid physics driving sickled and deformed RBCs to the vascular wall (known as margination of flow) - all of these come together to orchestrate VOC. Microfluidic technology in sickle research was primarily adopted to benefit from mimicking the microvascular network to observe RBC flow under low oxygen conditions as models of VOC. However, over the last decade, microfluidics has evolved as a valuable tool to extract biophysical characteristics of sickle red cells, measure deformability of sickle red cells under simulated oxygen gradient and shear, drug testing, models of intercellular interaction on endothelialized or adhesion molecule-functionalized channels to understand adhesion in sickle microenvironment, characterizing biomechanics and microrheology, biomarker identification, and last but not least, for developing point-of-care diagnostic technologies for low resource setting. Several of these platforms have already demonstrated true potential to be translated from bench to bedside. Emerging microfluidics-based technologies for studying heterotypic cell-cell interactions, organ-on-chip application and drug dosage screening can be employed to sickle research field due to their wide-ranging advantages.

MeSH

Drug Evaluation, Preclinical, Anemia, Sickle Cell, Acute Chest Syndrome, Pain, Cells, Exosomes, Research, Blood, Beds, Tissue Adhesions, Microfluidics, Point-Of-Care Systems, Hemoglobins, Hand-Foot Syndrome

Cited by

• Extracellular Vesicles in Sickle Cell Disease: A Promising Tool. Bioengineering (Basel), 2022
• Anticancer Drugs Paclitaxel, Carboplatin, Doxorubicin, and Cyclophosphamide Alter the Biophysical Characteristics of Red Blood Cells, In Vitro. Biology (Basel), 2023
• Microfluidics Approach to the Mechanical Properties of Red Blood Cell Membrane and Their Effect on Blood Rheology. Membranes (Basel), 2022
• The phenotypes of sickle cell disease: strategies to aid the identification of undiagnosed patients in the Italian landscape. Ital J Pediatr, 2025
• Fabrication and Manipulation of Non-Spherical Particles in Microfluidic Channels: A Review. Micromachines (Basel), 2022
• Low-cost optical sensors in electrified lab-on-a-disc platforms: liquid-phase boundary detection and automated diagnostics. Microsyst Nanoeng, 2025
• Guidelines for the management of emergencies and critical illness in pediatric and adult patients with sickle cell disease. Ann Intensive Care, 2025
• Next generation microfluidics: fulfilling the promise of lab-on-a-chip technologies. Lab Chip, 2024
• Microfluidic Characterization of Red Blood Cells Microcirculation under Oxidative Stress. Cells, 2022